ProQR Therapeutics (NASDAQ:PRQR) Issues Quarterly Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15), FiscalAI reports. The firm had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.

ProQR Therapeutics Stock Down 1.5%

Shares of NASDAQ PRQR traded down $0.02 during trading on Tuesday, reaching $1.59. 47,243 shares of the company traded hands, compared to its average volume of 521,290. The firm has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.89. ProQR Therapeutics has a 52-week low of $1.33 and a 52-week high of $3.10. The stock has a market capitalization of $167.10 million, a PE ratio of -3.45 and a beta of 0.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. increased its stake in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares in the last quarter. Guggenheim Capital LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter worth $35,000. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth about $51,000. Simplex Trading LLC increased its stake in ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after acquiring an additional 44,169 shares during the last quarter. Finally, Persistent Asset Partners Ltd lifted its position in ProQR Therapeutics by 24.5% during the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares during the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Oppenheimer began coverage on shares of ProQR Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price target on the stock. Wall Street Zen raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Tuesday, April 21st. Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, April 9th. Finally, Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.